These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

994 related articles for article (PubMed ID: 25338550)

  • 1. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia.
    Cavic M; Krivokuca A; Boljevic I; Brotto K; Jovanovic K; Tanic M; Filipovic L; Zec M; Malisic E; Jankovic R; Radulovic S
    J BUON; 2016; 21(5):1287-1295. PubMed ID: 27837635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
    Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
    Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
    Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
    Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
    McDermott U; Settleman J
    J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine.
    Feng F; Shen B; Mou X; Li Y; Li H
    J Genet Genomics; 2021 Jul; 48(7):540-551. PubMed ID: 34023295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
    Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
    Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.
    Lauschke VM; Milani L; Ingelman-Sundberg M
    AAPS J; 2017 Nov; 20(1):4. PubMed ID: 29181807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
    Yan L; Beckman RA
    Biotechniques; 2005 Oct; 39(4):565-8. PubMed ID: 16235569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.
    Kamel HFM; Al-Amodi HSAB
    Genomics Proteomics Bioinformatics; 2017 Aug; 15(4):220-235. PubMed ID: 28813639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lung Cancer].
    Yoshida K; Kono T
    Gan To Kagaku Ryoho; 2016 Nov; 43(11):1321-1325. PubMed ID: 27899772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.